- Home
- MTVA vs GOVX Comparison
MTVA vs GOVX Comparison
Compare MTVA & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- GOVX
- Stock Information
- Founded
- MTVA 2014
- GOVX 2001
- Country
- MTVA United States
- GOVX United States
- Employees
- MTVA N/A
- GOVX N/A
- Industry
- MTVA
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- MTVA
- GOVX Health Care
- Exchange
- MTVA NYSE
- GOVX Nasdaq
- Market Cap
- MTVA 15.1M
- GOVX 15.5M
- IPO Year
- MTVA N/A
- GOVX N/A
- Fundamental
- Price
- MTVA $0.69
- GOVX $1.12
- Analyst Decision
- MTVA Strong Buy
- GOVX Strong Buy
- Analyst Count
- MTVA 2
- GOVX 5
- Target Price
- MTVA $7.50
- GOVX $12.40
- AVG Volume (30 Days)
- MTVA 599.8K
- GOVX 270.4K
- Earning Date
- MTVA 05-14-2025
- GOVX 08-05-2025
- Dividend Yield
- MTVA N/A
- GOVX N/A
- EPS Growth
- MTVA N/A
- GOVX N/A
- EPS
- MTVA N/A
- GOVX N/A
- Revenue
- MTVA N/A
- GOVX $5,591,576.00
- Revenue This Year
- MTVA N/A
- GOVX N/A
- Revenue Next Year
- MTVA N/A
- GOVX N/A
- P/E Ratio
- MTVA N/A
- GOVX N/A
- Revenue Growth
- MTVA N/A
- GOVX N/A
- 52 Week Low
- MTVA $0.63
- GOVX $0.73
- 52 Week High
- MTVA $5.30
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- GOVX 58.57
- Support Level
- MTVA N/A
- GOVX $1.00
- Resistance Level
- MTVA N/A
- GOVX $1.14
- Average True Range (ATR)
- MTVA 0.00
- GOVX 0.07
- MACD
- MTVA 0.00
- GOVX 0.02
- Stochastic Oscillator
- MTVA 0.00
- GOVX 82.61
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.